Cancer Biology Research Center (CBC)
The mission of the Cancer Biology Research Center (CBC) is to advance understanding,
prevention, diagnosis, and treatment of cancer by generating new knowledge in cancer
biology and therapy and by participating in the application of this knowledge to translational
and clinical cancer research.
Research Groups and Infrastructures
The CBC is currently directed by Dr. M.-H. Wang with eighteen members across SOP,
SOM, and Amarillo VA Medical Center. The members are located either in SOP main building
or in adjacent Amarillo Research Building. Current members include: Drs. Fakhrul Ahsan,
Zonghan Dai, Jayarama Gunaje, Cheng Jiang, Lili Li, Xinli Liu, Paul Lockman, Junxuan
Lu, U.S. Rao, Quentin Smith, Sanjay Srivastava, K.S. Srivenugopal, Yunxia Tao, Wei
Wang, Stephen Wright, Jinhui Zhang, Ruiwen Zhang, and Yong Zhang. In addition, more
than 15 postdoctoral fellows and 35 graduated students are working with the CBC members
in various cancer-related projects.
Based on members’ background and expertise, the CBC has been organized into three
project targeted units: i) Cancer Chemoprevention: studying natural products and chemicals that potentially prevent tumor initiation
and progression. ii) Cancer Biology & Pathogenesis: studying multi-signaling cascades that regulate cancer malignancy and phenotype.
iii) Cancer Therapeutics & Therapy: developing potential anti-cancer therapeutics and studying mechanisms to overcome
cancer drug resistance. The CBC also has an Advanced Cancer Cell Image/Analysis core
with following major equipment: FACSAria flow-cytometer with cell sorting, Olympus
multiphoton laser scanning microscope, Caliper IVIS/Lumina XR animal image system,
GeneAMP5700 real-time PCR; Bio-Rad 5000 VersaDoc Image System; Leica TCS-SL Confocal
Spectral Microscope System, Olympus DSU Confocal microscope; GenePix Pro4200A DNA/Protein
Microarray (ARB); MSL-HPLC, and other necessary equipment. These advanced instruments
allow the CBC members and their associates in-depth analysis of molecular events occurred
during cancer progression and drug treatment.
Background & Accomplishments
The CBC was formed in 1999 with common interests and goals shared by several faculty
members in the School of Pharmacy. The goal is to determine molecular mechanisms of
cancer malignancy with specific aims to develop advanced anti-cancer therapeutics
for effective clinical treatment.
Over the last 10 years, the CBC the significantly expanded into three major cancer
research areas: Chemoprevention, Cancer Biology, and Experimental Therapeutics. More
than 20 research grants with total support of >$10 million research dollars were obtained
from NIH, DOD, CPRIT, and other funding agencies. Currently, the CBC has more than
1.5 million dollars annually, which support various biomedical and pharmaceutical
research projects.This is a remarkable achievement reflecting the members’ effort
and dedication considering the current funding scenario.
Through intensive collaborative and innovative research, the CBC members have made
numerous discoveries and published more than 100 articles in highly peer-reviewed
journals including Cancer Research, Clinical Cancer Research, Oncogene, Molecular
Cancer Therapeutics, Molecular Cancer, Molecular Pharmaceutics, JBC, Carcinogenesis,
and other peer-reviewed journals. The CBC members also serve in various national committees,
such as NIH Study Sections, DOD grant review panels, various journal editorial boards,
and act as organizers & sections chairs for various local, national, and international
In summary the CBC is currently a vital research component in the School of Pharmacy
and a major research force in the TTU system wide cancer research community.